Please Wait...

Classic Blog

Necessity and Associated Benefits of Having Post-Approval Specific Technology

  • 0
  • 26 Jan

Over the last decade, across the globe, the regulatory landscape has changed considerably, with greater focus and awareness on pharmaceutical products post-approval. Legislation, coupled with public concerns about the safety of marketed drugs and the need to evaluate safety and effectiveness of the marketed products in a real-world setting is forcing many companies to embark on post-approval research.

Read More

Bioclinica Demonstrates EHR to CDASH (E2C) Standard

  • 0
  • 06 Jan

Ever since the US FDA introduced Meaningful Use requirements calling for medical practices to begin using EHR systems, the race was on to find a way to pull the data from EHR systems into the EDC systems electronically.  Many options have been tried − most focused on accessing the data from the EHR in the native HL7 format.  While this solution works, it's not easy to do. One of the stumbling blocks is the inability of site personnel to access this type of data from their EHR.

Read More
2015 Asia Events

Expanding Opportunities for Drug Development in Asia

  • 0
  • 06 Oct

Over the last decade, R&D activities, pharmaceutical market size, and the number of clinical trials in Asia has grown tremendously.  As a result, Asian biopharmaceutical companies are developing more products for commercialization in the global market, and International drug development service companies have moved many R&D functions and commercial operations to the APAC region.

Read More
CSF biomarkers & Alzheimer's Disease

CSF Biomarkers and the advancement of Alzheimer's Disease Trials

  • 0
  • 03 Aug

The Importance of Early Diagnosis for AD Last month, scientists, clinicians, drug sponsors, and regulators gathered in our nation's capital at the annual Alzheimer's Association International Conference (AAIC) to share recent advances in AD research and clinical drug development.

Read More

How RBM Technology Strengthens Sponsor-Site Ties

  • 0
  • 10 Jun

Why does it seem like problems surface at clinical research sites right about when the study team is either busy preparing for a monitoring visit or immediately following one?

Read More
Imaging biomarkers, molecular imaging in oncology clinical trials

Leveraging Imaging Biomarkers to Improve Drug Development

  • 0
  • 02 Jun

Clinicians need ways to better predict patient responses

The estimated cost for developing a drug is approaching upwards of $5 Billion dollars with a process spanning well over a decade. Coupled with high failure rates in late phase clinical trials and increased complexities in acquiring and analyzing clinical trial data, traditional approaches based on the premise of "one size fits all" are becoming less cost effective and suboptimal.

Read More

eClinical Lessons Learned

  • 0
  • 01 Jun

Part 2 of 2

In my last blog, I shared risk-based monitoring (RBM) lessons learned and RBM insights from the  BioClinica 5th Annual BioClinica Global User Conference held in May in Orlando, Florida.  Here is a recap of other eClinical sessions I had the pleasure of attending.

Read More

Risk-Based Monitoring: Lessons Learned

  • 0
  • 01 Jun

Part 1 of 2 It was both a great learning experience and fun to participate in another user conference, BioClinica's fifth and my third since joining the company in 2013. We spent quality time with both long-time collaborators and first-time partners.

Read More

The Future of Clinical Trial Data Management and Technology's Growing Impact

  • 0
  • 22 May
At BioClinica's 2015 Global User Conference, I had the pleasure of leading an expert panel discussion on the future of data management. I would like to share some highlights from my perspective. Panel participants were Daun Bahr, senior director data management Orexigen; Queennette Santiago, head of data management Ultragenyx; Clara Plascencia, associate director of clinical data management Pharmacyclics; and Ann Seibel, clinical data manager BioClinica.
Read More

Remote Monitoring in RBM Q&A

  • 0
  • 12 May

We promised to answer questions that came in following a recent BioClinica webinar. Here RBM expert, Trevor McCaw, addresses a two-part inquiry on remote monitoring.

Read More
Risk-Based Monitoring: RBM Expert Opinion

Risk-Based Monitoring: 5 Key Questions

  • 0
  • 28 Apr

RBM experts Courtney McBean and Mireille Zerola, a member of the TransCelerate RBM work stream, address five commonly asked questions (and clear up a few misconceptions) surrounding RBM and its underlying methodology.

Read More

Data Champions in Risk-Based Monitoring

  • 0
  • 20 Apr

Data Champions in Risk-Based Monitoring

The centuries-old saying, "knowledge is power" coined by Francis Bacon in 1597, is fitting in our risk-based monitoring (RBM) conversations today. In research − trial data is power. This is becoming even more apparent as our data is being used in new ways to inform monitoring and study management decisions to run better trials.

Read More

Pages

Required eCTD Submissions as of May 5, 2017 – Are You Ready?

  • 0
  • 10 Apr

The electronic common technical document (eCTD) is an interface for the pharmaceutical industry to transfer regulatory information based on the Common Technical Document (CTD) format, which is an agreed common format for applications that will be acceptable in all three ICH-Regions (US, EU & Japan) and other countries.

Read More

Biomarkers and Personalized Medicine: Essential Tools

  • 0
  • 28 Mar

The use of biomarkers is expanding across all stages in the drug development process, helping bring about new and innovative practices in the treatment of many diseases, including Alzheimer's and cancer. With their ability to revolutionize development of advanced therapeutics, biomarkers have become essential tools.

Read More

Successful Direct-to-Patient Shipping of Study Drugs

  • 0
  • 27 Mar

Clinical trials for patients with rare, debilitating diseases who have limited mobility and greater caregiving requirements can be challenging, particularly for clinic visits and medication adherence. But, we like a challenge. In a recent clinical trial, we collaborated with the sponsor to successfully ship the study drugs directly from the depot to a sample of US-based patients with a rare, progressive debilitating disease characterized by motor, cognitive and behavioral symptoms.

Read More

Meet the Bioclinica Financial Lifecycle Solutions Team: Bob Gabriel, Senior Vice President and General Manager, Bioclinica FLS

  • 0
  • 17 Mar

Bob Gabriel is the Senior Vice President and General Manager of Bioclinica's Financial Lifecycle Solutions (FLS) division. The FLS suite of financial lifecycle products assists with managing the global automation and financial management of clinical trials and includes ClinPay, a proprietary transaction engine and secure online clinical trial payment network; ClinPlan, a budget management and cash forecasting solution; and ClinDebit, a patient reimbursement solution.

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @eClinical_Jen: FREE on-demand webinars from @bioclinica on EDC, Imaging, RBM, and Clinical Trial Management. Tell them I sent you! http…
bioclinica (14 hours ago)
Excited to host NJ Lt. Gov. Kim Guadagno, clients, partners 9/28 in Princeton! In the area? Join us ! RSVP… https://t.co/PrfyxvasGb
bioclinica (Yesterday)
Be sure to follow #ThankAScientist all week to thank researchers for the work they do! https://t.co/Sfi9mmHbSk… https://t.co/y9ZhBXsIzu
bioclinica (2 days ago)
Cardiovascular imaging use is growing in non-cardiovascular areas #ClinicalTrials. See where in Tim Crowe's blog… https://t.co/dYjPBC0Wtn
bioclinica (2 days ago)
RT @Xtalks: Cardiovascular Safety in #Biopharmaceutical Product Development - From QT Prolongation and Beyond @bioclinica https://t.co/mCk1…
bioclinica (2 days ago)
RT @Xtalks: How Innovations in Data Visualization Are Accelerating Data Cleaning and Improving Quality @bioclinica https://t.co/vfLU8pS9Rd
bioclinica (2 days ago)

Latest Blogs: